rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Elaine J. Heron

Director

Company insider

Files Form 4 as: Director, Vaxart; Director, Palvella Therapeutics; Director, BioMarin Pharmaceutical.

Every Form 4 they filed

In numbers

Trades disclosed
160
Buys
2
Sells
9
Bought
$616K
Sold
$8.5M
Companies
3
Companies where not an officer
3
First trade
12 Jul 2006
Last trade
16 Jul 2026
Last filed
17 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
VaxartDirector · Biotechnology · last 16 Jul 20261 buy · 0 sells
PVLA Palvella TherapeuticsDirector · Biotechnology · last 10 Jun 20261 buy · 0 sells
BMRN BioMarin PharmaceuticalDirector · Biotechnology · last 3 Jun 20240 buys · 9 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jul 2026filed 17 Jul 2026VaxartBiotechnologySEC FORM 4 Code A—39,400 at $0.00filing
16 Jul 2026filed 17 Jul 2026Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—78,700 at $0.00filing
16 Jul 2026filed 17 Jul 2026Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—78,700 at $0.00filing
16 Jul 2026filed 17 Jul 2026VaxartBiotechnologySEC FORM 4 Code A—39,400 at $0.00filing
10 Jun 2026filed 12 Jun 2026PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,000 at $0.00filing
10 Jun 2026filed 12 Jun 2026PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—3,000 at $0.00filing
27 Feb 2026filed 2 Mar 2026PVLA Palvella TherapeuticsBiotechnologySEC FORM 4 Bought$300K2,400 at $125.00filing
27 Feb 2026filed 2 Mar 2026PVLA Palvella TherapeuticsBiotechnologySEC FORM 4 Bought$300K2,400 at $125.00filing
17 Nov 2025filed 21 Nov 2025VaxartBiotechnologySEC FORM 4 Bought$9,05523,217 at $0.39filing
17 Nov 2025filed 21 Nov 2025VaxartBiotechnologySEC FORM 4 Bought$6,88116,783 at $0.41filing
13 Jun 2025filed 16 Jun 2025Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—95,400 at $0.00filing
13 Jun 2025filed 16 Jun 2025VaxartBiotechnologySEC FORM 4 Code A—16,000 at $0.00filing
10 Jun 2025filed 11 Jun 2025PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—12,350 at $0.00filing
13 Dec 2024filed 17 Dec 2024PVLA Palvella Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—24,700 at $0.00filing
11 Jun 2024filed 12 Jun 2024Vaxartoption or derivative · BiotechnologySEC FORM 4 Code A—95,400 at $0.00filing
11 Jun 2024filed 12 Jun 2024VaxartBiotechnologySEC FORM 4 Code A—16,000 at $0.00filing
3 Jun 2024filed 4 Jun 2024BMRN BioMarin Pharmaceuticaloption or derivative · BiotechnologySEC FORM 4 Code M—5,047 at $0.00filing
3 Jun 2024filed 4 Jun 2024BMRN BioMarin PharmaceuticalBiotechnologySEC FORM 4 Code M$318K5,047 at $63.10filing
3 Jun 2024filed 4 Jun 2024BMRN BioMarin PharmaceuticalBiotechnologySEC FORM 4 Code F$318K4,168 at $76.41filing
21 May 2024filed 23 May 2024BMRN BioMarin PharmaceuticalBiotechnologySEC FORM 4 Code A—4,720 at $0.00filing

Sectors

Health Care11

Buys in green, sells in red, by the company’s sector.

Related people

Raquel C. BonoDirector · Director at Vaxart, filing Form 4 there in the last year
George M. JenkinsDirector · Director at Palvella Therapeutics, filing Form 4 there in the last year
Kathleen GoinChief Operating Officer · Chief Operating Officer at Palvella Therapeutics, filing Form 4 there in the last year
Christopher P. KiritsyDirector · Director at Palvella Therapeutics, filing Form 4 there in the last year
Kevin FinneyDirector · Director at Vaxart, filing Form 4 there in the last year
George Eric DavisEVP, Chief Legal Officer · Also traded BMRN in the last 90 days